This Aclaris Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Analysts downgraded SWK, SHLS, TSN, IDA and ACRS, with mixed price-target changes; ACRS saw the steepest cut, from $8 to $3.

Last updated: 2026-11-18 05:15:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Aclaris Therapeutics, Inc. (ACRS) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $3.39, with a market capitalization of $621.76M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.34 to $6.60. This page covers its latest market performance, valuation, price trends and company information.
$621.76M | |
$3.47 | |
$3.92 | |
$3.33 | |
$3.61 | |
2.89M | |
3.05M | |
-- | |
$6.60 | |
$2.34 | |
-- | |
-- |
Aclaris Therapeutics, Inc. (ACRS) last closed at $3.39 as of 2026-11-18 00:44:00, down 5.96% ($0.21) from the previous close of $3.61.
During the latest regular trading session, ACRS traded between $3.33 and $3.92, with a volume of 2.89M shares. The closing price was near the lower end and near the lower end of its 52-week range.
ACRS is up 0.90% as of the last close.
Over the past seven days, Aclaris Therapeutics, Inc. (ACRS) moved from $3.90 to $3.39, representing a decline of 13.21% ($0.52).
The stock traded between $3.28 and $4.40 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 3.14 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 24.5%
ACRS is currently trading at $3.39, placing it 24.5% of the way from its 52-week low of $2.34 to its 52-week high of $6.60. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 73 |
| Exchange | NASDAQ |
| Company Website |
Latest news related to Aclaris Therapeutics, Inc. and ACRS stock.
Analysts downgraded SWK, SHLS, TSN, IDA and ACRS, with mixed price-target changes; ACRS saw the steepest cut, from $8 to $3.
Wedbush analyst Martin Fan downgrades Aclaris Therapeutics (NASDAQ:ACRS) from Outperform to Neutral and lowers the price target from $8 to $3.
U.S. stock futures fell as Red Cat plunged 25.8% after weak Q3 results and withdrawing FY26 guidance; several stocks also declined premarket.
Aclaris Therapeutics misses Phase 2 bosakitug endpoints but launches its Phase 2b modzatinib trial for moderate-to-severe lichen planus.
U.S. stock futures fell as Aclaris plunged 21% after its dermatitis trial failed; Summit and other stocks also dropped in premarket trading.
Eligible investors can buy real shares of Aclaris Therapeutics, Inc. (ACRS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to ACRS, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between ACRS shares and USD.
ACRS Shares to USD
1.00 ACRS shares = 3.385 USD
Calculations are estimates based on the latest available price and are for reference only.